TD Cowen analyst Joseph Thome has maintained their bullish stance on ARWR stock, giving a Buy rating on November 19.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Joseph Thome has given his Buy rating due to a combination of factors that highlight Arrowhead Pharmaceuticals’ promising prospects. The recent approval and launch of Redemplo for familial chylomicronemia syndrome (FCS) with a strategic pricing model indicates strong market potential. The company has set a single pricing strategy for Redemplo, which is expected to drive sales growth, with projections reaching approximately $1.4 billion by 2035, contingent on further approvals.
Additionally, Arrowhead’s ongoing developments in obesity treatments, specifically ARO-ALK7 and ARO-INHBE, show potential for significant impact in the obesity market. These treatments are being explored for their efficacy as monotherapies and in combination with existing GLP-1 agonists, aiming to offer convenient dosing and effective weight management solutions. The company’s strategic partnerships, such as the one with Sarepta, which has already resulted in a $200 million milestone, further bolster its growth outlook. These factors collectively underpin Thome’s optimistic Buy rating for Arrowhead Pharmaceuticals.
In another report released on November 19, H.C. Wainwright also reiterated a Buy rating on the stock with a $80.00 price target.